High Flow Nasal Therapy in Covid 19 Patient
Predictors of Success of High Flow Nasal Therapy in Covid 19 Patients
1 other identifier
observational
60
0 countries
N/A
Brief Summary
This study aims to To identify factors that predict success of high flow nasal therapy in covid19 patients .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2021
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 25, 2021
CompletedFirst Posted
Study publicly available on registry
October 26, 2021
CompletedStudy Start
First participant enrolled
November 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2022
CompletedOctober 26, 2021
October 1, 2021
10 months
October 25, 2021
October 25, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
predictors of success of high flow nasal therapy in covid 19 patients
This study aims to To identify factors that predict success of high flow nasal therapy in covid19 patients
Baseline
Study Arms (2)
group A
Covidpatient Who pass on high flow nasal therapy
group B
Covidpatient who failed on high flow nasal therapy and need NIV
Interventions
effect of high flow nasal therapy in covid 19 patients who pass and who need non invasive
Eligibility Criteria
1. demographic data including age, sex, smoking history, educational level. 2. Duration of illness before admission, clinical presentation, presence of co morbidities, BMI. 3. Vital signs, and radiologic findings 4. ABG at admission and (half an hour, 2hr, 24 hr, and 48hr)later on. 5. SPO2, FIO2, and respiratory rate at admission for calculating ROX index (SPO2/FIO2)/RR. 6. GCC, and APACHI score at time of admission. 7. Inflammatory markers at time of admission (CBC with differential, CRP, ferritin, D dimer, LDH), in addition to liver and renal function. At the end of the study patients will be claccifiedin to two groups based on success of high flow nasal therapy: Group A Covidpatient Who pass on high flow nasal therapy Group B Covidpatient who failed on nasal therapy and need NIV
You may qualify if:
- All Patients above 18 y old that will be diagnosed as COVID 19 based on PCR testing, who fulfil criteria that indicate need for high flow nasal therapy.
You may not qualify if:
- o Children less than 18 y old
- Oropharyngeal and Nasopharyngeal swap negative patients
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Nishimura M. High-Flow Nasal Cannula Oxygen Therapy in Adults: Physiological Benefits, Indication, Clinical Benefits, and Adverse Effects. Respir Care. 2016 Apr;61(4):529-41. doi: 10.4187/respcare.04577.
PMID: 27016353BACKGROUND
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Assistant Lecturer
Study Record Dates
First Submitted
October 25, 2021
First Posted
October 26, 2021
Study Start
November 1, 2021
Primary Completion
August 31, 2022
Study Completion
September 30, 2022
Last Updated
October 26, 2021
Record last verified: 2021-10